New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X L /BCL-2 inhibition with navitoclax.

MLA

Pemmaraju, Naveen, et al. “New Era for Myelofibrosis Treatment with Novel Agents beyond Janus Kinase-Inhibitor Monotherapy: Focus on Clinical Development of BCL-X L /BCL-2 Inhibition with Navitoclax.” Cancer, vol. 129, no. 22, Nov. 2023, pp. 3535–45. EBSCOhost, https://doi.org/10.1002/cncr.34986.

APA

Pemmaraju, N., Garcia, J. S., Perkins, A., Harb, J. G., Souers, A. J., Werner, M. E., Brown, C. M., & Passamonti, F. (2023). New era for myelofibrosis treatment with novel agents beyond Janus kinase-inhibitor monotherapy: Focus on clinical development of BCL-X L /BCL-2 inhibition with navitoclax. Cancer, 129(22), 3535–3545. https://doi.org/10.1002/cncr.34986

Chicago

Pemmaraju, Naveen, Jacqueline S Garcia, Andrew Perkins, Jason G Harb, Andrew J Souers, Michael E Werner, Christopher M Brown, and Francesco Passamonti. 2023. “New Era for Myelofibrosis Treatment with Novel Agents beyond Janus Kinase-Inhibitor Monotherapy: Focus on Clinical Development of BCL-X L /BCL-2 Inhibition with Navitoclax.” Cancer 129 (22): 3535–45. doi:10.1002/cncr.34986.